TP53 and B-cell chronic lymphocytic leukemia: Acalabrutinib monotherapy was evaluated in relapsed or refractory CLL in the ASCEND trial, which demonstrated its superiority over idelalisib-rituximab or BR, regardless of the presence of TP53 alterations.